ophthalmology gene therapy in - nysgeneticstaskforce.org · ophthalmology •dec 19, 1917 the fda...
TRANSCRIPT
![Page 1: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/1.jpg)
Gene Therapy in OphthalmologyIrene H MaumeneeColumbia University
![Page 2: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/2.jpg)
Gene Therapy in Ophthalmology
No conflict to report
![Page 3: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/3.jpg)
![Page 4: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/4.jpg)
Gene Therapy in Ophthalmology
• Dec 19, 1917 the FDA issued an approval letter for Luxturna
• Luxturna is used in adeno-associated virus vector-based (AAV) gene therapy of RPE65, a subtype of Leber congenital amaurosis
• Manufacturer: Spark Therapeutics, Inc.
![Page 5: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/5.jpg)
Gene Therapy in Ophthalmology
• Indication: Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients had to have evidence of viable retinal cells as determined by the treating physician(s).
![Page 6: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/6.jpg)
RPE 65 Phenotype
• Early severe disorder• Retinal pigmentary mottling, atrophy• Gradual improvement followed by progressive
loss• Presence of nightblindness• Refractive status, hypermetropia, myopia
![Page 7: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/7.jpg)
RPE65
![Page 8: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/8.jpg)
![Page 9: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/9.jpg)
![Page 10: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/10.jpg)
![Page 11: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/11.jpg)
Gene Therapy in Ophthalmology
![Page 12: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/12.jpg)
Gene Therapy in Ophthalmology
• Drug is injected into the subretinal space • Immediate post-op decline of acuity• Positive effect is seen within months of
injection• Measured after one year in a mobility test,
where obstacles are placed in a maze to be navigated in different light conditions
![Page 13: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/13.jpg)
Gene Therapy in Ophthalmology
• Cost of the drug: $875,000 for both eyes (500,000 for one eye)
• Unknown how long the positive effect will last
• Animal model: Briard dog• Effect lasted throughout the dog’s life span
of 10-12 years
![Page 14: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/14.jpg)
Briard Dog
![Page 15: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/15.jpg)
Gene Therapy in Ophthalmology
Search for: •Treatment hypotheses for additional ocular diseases
•other modes of gene therapy•other approaches to drug delivery•animal models
![Page 16: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/16.jpg)
Gene Therapy in Ophthalmology
Led to immediate use of AAV or CRISPR technology in other retinal dystrophies, which now are undergoing clinical trials:
•Achromatopsia: CNGB3; CNGA3; BCM •Best disease: BEST1•Choroideremia: CHM•Leber congenital amaurosis: GUCY2D; CEP290•Rp4: RHO•Stargardt disease: ABCA4•X-linked Rp: RPGR•X-linked retinoschisis: XLRS
![Page 17: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/17.jpg)
Achromatopsia
• Lifelong, stable poor acuity• Photophobia• Nystagmus• Normal functioning in mesopic conditions• Diagnosis confirmed on electroretinography• Give patients red tinted glasses• Red contacts may be well tolerated for years
![Page 18: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/18.jpg)
Achromatopsia
![Page 19: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/19.jpg)
Achromatopsia
![Page 20: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/20.jpg)
Achromatopsia
![Page 21: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/21.jpg)
Achromatopsia
• CNGB3• CNGA3• Cone transducin GNAT2• Cone Phosphodiesterase deficiency
PDE6C • Incomplete achromatopsia – Blue Cone
Monochromacy – X-linked
![Page 22: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/22.jpg)
Achromatopsia
• 1148delC in CNGB3 is the most common mutation leading to achromatopsia
• It originated in Aland, Finland and has spread around the world
![Page 23: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/23.jpg)
X-linked Incomplete Achromatopsia
• Blue cone monochromacy• Caused by deletions of the promoter
region of the red-green genes near the terminal end of the X-chromosome
![Page 24: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/24.jpg)
X-linked Incomplete Achromatopsia
• Visual acuity is poor in first five years of life
• Nystagmus; photophobia• Slow improvement is seen up to 20/60
acuity• Recurring decline of acuity in late teens
down to 2-3/200
![Page 25: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/25.jpg)
![Page 26: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/26.jpg)
![Page 27: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/27.jpg)
![Page 28: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/28.jpg)
![Page 29: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/29.jpg)
Progress in Leber Congenital Amaurosis
Leber congenital amaurosis presents in infancy with:– Profound loss of vision– Nystagmus– Sluggish pupillary responses– Markedly reduced to abolished ERG
![Page 30: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/30.jpg)
![Page 31: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/31.jpg)
![Page 32: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/32.jpg)
Progress in Leber Congenital Amaurosis
Incidence
• 1- 2 in 100,000• 5% of all inherited retinal
dystrophies
![Page 33: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/33.jpg)
Progress in Leber Congenital Amaurosis
This disease is separated from retinitis pigmentosa because of its congenital onset and more significant impact on vision. That separation is arbitrary
LCA is among the important groups of human diseases to be understood in order to develop methods of treatment and prevention
![Page 34: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/34.jpg)
Progress in Leber Congenital amaurosis
• Identification of new loci • Identification of new genes in chromosomal
regions of positive linkage• Mutation analysis• Screening and sequencing of known genes
($2,500)• Whole exome sequencing ($6,000)• Whole genome sequencing ($2,500)
![Page 35: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/35.jpg)
Leber Congenital AmaurosisLCA1 GUCY2D LCA2 RPE65LCA3 SPATA7LCA4 CRXLCA5 LEBERCILINLCA6 AIPL1LCA7 RPGRIP1 LCA8 CRB1 LCA9 NMNAT1LCA10 RDH12
LCA11 IMPDH1LCA12 CEP290LCA13 RD3LCA14 TULP1LCA15 NPHN5LCA16 IQCB1LCA17 LCA18 OTX2 LCA19 CABP4LCA20 DTHT1
![Page 36: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/36.jpg)
Progress in Leber congenital amaurosis
• GUCY2D cGMP levels in photoreceptors• RPE65 Vitamin A metabolism• SPATA7 Protein transport• CRX PR development, maintenance• Lebercilin Protein transport• AIPL1 PR development, protein folding• RPGRIP1 Protein transport
![Page 37: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/37.jpg)
Progress in Leber Congenital Amaurosis
• GUCY2D Regulation of cyclic GMP levels• CRB1 Mueller cell – photoreceptor
interaction (rods and cones)• NMNAT1 Neuroprotection• RDH12 PR retinol dehydrogenase• IMPDH1 Guanine synthesis• CEP290 Centrosomal protein• LCA5 Protein transport
![Page 38: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/38.jpg)
Gene Therapy in Ophthalmology
Biotech Companies:•Spark•Abeona•AGTC•Biogen•Novartis
![Page 39: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/39.jpg)
![Page 40: Ophthalmology Gene Therapy in - nysgeneticstaskforce.org · Ophthalmology •Dec 19, 1917 the FDA issued an approval letter for Luxturna •Luxturna is used in adeno-associated virus](https://reader034.vdocument.in/reader034/viewer/2022042218/5ec392148634de7cdd1086d1/html5/thumbnails/40.jpg)
Gene Therapy in Ophthalmology
Thank You